COPY OF PAPERS ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kristof CHWALISZ et al.

Serial No.: 10/043,232

Group Art Unit: 1617

Filed: January 14, 2002

Examiner: TBA

IMPLANTATION RATES AFTER IN VITRO FERTILIZATION, AND TREATMENT OF INFERTILITY AND EARLY PREGNANCY LOSS WITH A NITRIC OXIDE DONOR OR SUBSTRATE ALONE OR IN COMBINATION WITH PROGESTERONE, AND A METHOD FOR CONTRACEPTION WITH NITRIC OXIDE INHIBITORS IN COMBINATION WITH ANTIPROGESTINS OR OTHER AGENTS

INF	<u> DRMA</u>	FION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98	
Assistant Commissioner for Patents Washington, D. C. 20231 I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed To: Commissioner of Patents, and Ifademarks,			
Sir:		Washington, D.C. 20231 On: 473/07 Name: Signature: Alanco Bandy	
	CITE	D MATERIALS Signature: / Diencol Surg Date: / Johnson	
	Appli	cant(s) hereby disclose the information listed in the attached form PTO-1449.	
		Copies of materials listed but not attached were cited in parent application Serial No. <u>09/162,446</u> ; see 37 C.F.R. § 1.98(d).	
		Copies of materials listed but not attached were cited in an International Search Report dated; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed	
	ADD:	ITIONAL INFORMATION	
	NON	E	
	LANC	GUAGE	
		All listed materials are in the English language; see 37 C.F.R. § 1.98.	
		Non-English language references:	
		☐ The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.	
		☐ (An) English-language translation(s) of the references: is (are) provided.	
		☐ A commercial English-language abstract of reference(s) is (are)	

·	An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).
<u>FEES</u>	
\boxtimes	No fee is required for this Information Disclosure Statement because:
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
	This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
	☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
	A fee is required for this Information Disclosure Statement:
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
	This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.
CERTI	FICATION
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\sum_\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nancy J. Axelrod, Reg. No. 44,014 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO& BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

FILED: <u>April 15, 2002</u>